Clinical trial
Randomized, Double-blind, Controlled Phase I/II Clinical Trial on the Tolerability, Safety, and Immunogenicity of Tetravalent Inactivated Enterovirus Vaccine (Vero Cell) in Healthy Adults and Children Aged 6 Months to 12 Years.
NCT06754384 is registered in ClinicalTrials.gov with Sinovac Biotech Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, Double-blind, Controlled Phase I/II Clinical Trial on the Tolerability, Safety, and Immunogenicity of Tetravalent Inactivated Enterovirus Vaccine (Vero Cell) in Healthy Adults and Children Aged 6 Months to 12 Years.
- Lead sponsor
- Sinovac Biotech Co., Ltd
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- January 15, 2025
- Completion date
- February 10, 2026
- Enrollment
- 552 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
hand, foot, and mouth disease (hfmd), herpangina